Stealth BioTherapeutics Awarded Grant from The Michael J. Fox Foundation to Support Development of SBT-272 in Parkinson’s Disease Press Release / August 9, 2023June 3, 2024
Stealth BioTherapeutics Announces SBT-272 Data Updates and Orphan Drug Designation for the Treatment of Amyotrophic Lateral Sclerosis (ALS) Press Release / November 1, 2022June 3, 2024
Stealth BioTherapeutics Presents New SBT-272 Data Demonstrating Improvement in Upper Motor Neuron Function in ALS Disease Model at Keystone Neurodegeneration Symposium Uncategorized / June 8, 2022June 3, 2024
Stealth BioTherapeutics Announces New SBT-272 Data and Trial Initiation Press Release / March 30, 2022June 3, 2024
Stealth BioTherapeutics Announces New Data on Complement Gene Expression and Cell Survival in Dry AMD to be Presented at ARVO (2022) Press Release / March 24, 2022June 3, 2024
